Enhanced pulmonary delivery of fluticasone propionate in rodents by mucus-penetrating nanoparticles
详细信息 查看全文
- 作者：Alexey Popov ; alexey.popov@kalarx.com" class="auth_mail" title="E-mail the corresponding author ; Lisa Schopf ; James Bourassa ; Hongming Chen
- 关键词：Drug delivery ; Fluticasone ; Inflammation ; Mucoadhesive ; Mucus-penetrating particles ; Nanoparticles ; Pulmonary
- 刊名：International Journal of Pharmaceutics
- 出版年：2016
- 出版时间：11 April 2016
- 年：2016
- 卷：502
- 期：1-2
- 页码：188-197
- 全文大小：914 K
文摘
Most attempts to achieve sustained drug delivery to pulmonary tissues using nanoparticles have focused on mucoadhesive particles (MAP). However, MAP become trapped in the luminal mucus layer and, as a result, are largely eliminated from the respiratory tract by mucociliary escalator and expiratory clearance, which undermines their sustained release potential. Recent studies have shown that mucus-penetrating particles (MPP) engineered to diffuse through mucus can avoid rapid mucociliary clearance in vivo and persist in the lung longer. Nonetheless, it has not been confirmed that MPP encapsulating small molecules can sustain drug release in the lung longer than MAP of similar size and core composition. As a proof of concept, we encapsulated fluticasone propionate (FP) into poly(lactide)-based MPP and MAP (both ∼200 nm diameter, ∼30–35% drug loading) and evaluated their pulmonary residence by measuring FP levels in mouse lungs over 24 h following intratracheal instillation. Furthermore, we evaluated the duration of action of FP MPP in a rat lung inflammation model compared to that of a non-encapsulated FP control. In rodents, pulmonary delivery of FP formulated as MPP provided a 60% higher local exposure compared to MAP and extended the single dose efficacy by at least 16 h compared to non-encapsulated FP.